MedTrace Logo

Neoadjuvant Chemotherapy Compared With Surgery for Esophageal Carcinoma

NCT05569668 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 826

Last updated 2022-10-06

No results posted yet for this study

Summary

Most ESCC received NAC in China without supportive evidence from local RCTs. The negative conclusion about NAC originated from Western countries in the 1990s. Whether two-field extensive mediastinal lymphadenectomy and paclitaxel/platinum-based chemotherapy results in better survival should be determined. As the highest ESCC incidence area worldwid, we tried to analyze this top with big data by using a single-center case-control retrospective PMS study. Paclitaxel- and platinum-based NAC combined with two-field of the extensive mediastinal lymphadenectomy might provide better survival benefits than primary esophagectomy for stage II/III SCC.

Conditions

  • Esophagus Cancer

Interventions

DRUG

Paclitaxel- and platinum-based chemotherapy

Neoadjuvant Chemotherapy

Sponsors & Collaborators

  • Henan Cancer Hospital

    lead OTHER_GOV

Principal Investigators

  • Yan Zheng, PhD, MD · Henan Cancer Hospital/The affiliated Cancer Hospital of ZhengZhou university

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-01-01
Primary Completion
2022-08-01
Completion
2022-08-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05569668 on ClinicalTrials.gov